Business Description
HLB Therapeutics Co Ltd
NAICS : 541519
ISIN : KR7115450009
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.84 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 1.1 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 11.53 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.7 | |||||
3-Year EPS without NRI Growth Rate | 14.4 | |||||
3-Year FCF Growth Rate | 54.6 | |||||
3-Year Book Growth Rate | 11.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.08 | |||||
9-Day RSI | 47.59 | |||||
14-Day RSI | 43.17 | |||||
6-1 Month Momentum % | 208.71 | |||||
12-1 Month Momentum % | 103.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.64 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.94 | |||||
Days Inventory | 44.23 | |||||
Days Sales Outstanding | 50.89 | |||||
Days Payable | 51.53 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.9 | |||||
Shareholder Yield % | 5.63 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 14.79 | |||||
Operating Margin % | -17.72 | |||||
Net Margin % | -3.26 | |||||
FCF Margin % | -29.11 | |||||
ROE % | -1.13 | |||||
ROA % | -0.88 | |||||
ROIC % | -5.94 | |||||
ROC (Joel Greenblatt) % | -4.96 | |||||
ROCE % | -0.55 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.72 | |||||
PB Ratio | 3.85 | |||||
Price-to-Tangible-Book | 7.75 | |||||
EV-to-EBIT | -649.92 | |||||
EV-to-EBITDA | 67.68 | |||||
EV-to-Revenue | 11.13 | |||||
EV-to-FCF | -36.78 | |||||
Price-to-Projected-FCF | 30.49 | |||||
Price-to-Median-PS-Value | 0.94 | |||||
Price-to-Net-Current-Asset-Value | 120.01 | |||||
Earnings Yield (Greenblatt) % | -0.15 | |||||
FCF Yield % | -2.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
HLB Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 56,234.374 | ||
EPS (TTM) (â‚©) | -19.228 | ||
Beta | -0.58 | ||
Volatility % | 105.46 | ||
14-Day RSI | 43.17 | ||
14-Day ATR (â‚©) | 847.508276 | ||
20-Day SMA (â‚©) | 8584 | ||
12-1 Month Momentum % | 103.91 | ||
52-Week Range (â‚©) | 2840.57971 - 17700 | ||
Shares Outstanding (Mil) | 76.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
HLB Therapeutics Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
HLB Therapeutics Co Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
HLB Therapeutics Co Ltd Frequently Asked Questions
What is HLB Therapeutics Co Ltd(XKRX:115450)'s stock price today?
When is next earnings date of HLB Therapeutics Co Ltd(XKRX:115450)?
Does HLB Therapeutics Co Ltd(XKRX:115450) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |